NanoViricides, Inc. (NASDAQ:NNVC) | WebDisclosure

Basculer en Français

9480	Companies
185559	Keywords
117951	Articles
99390	Press releases

Home
Companies
NanoViricides, Inc.

BRIEF

published on 06/18/2025 at 12:35, 5 months 17 days ago

NanoViricides présente le NV-387 comme un antiviral de premier plan

Antiviral NV-387 Variantes De La COVID Menace De Grippe Aviaire Efficacité À Large Spectre Préparation Aux Pandémies
PRESS RELEASE

published on 06/18/2025 at 12:30, 5 months 17 days ago

With Rising Variants of COVID and Bird Flu, the Single Broad-Spectrum Antiviral NV-387 Would be the Best Partner for Preparedness, Says NanoViricides' Dr. Diwan
NanoViricides, Inc. announces the effectiveness of broad-spectrum antiviral drug NV-387 against COVID variants and Bird Flu, positioning it well for pandemic preparedness

NanoViricides NV-387 Antiviral Drug Bird Flu COVID Variants
BRIEF

published on 06/04/2025 at 13:00, 6 months 1 day ago

NanoViricides se prépare à une étude animale sur un médicament contre la rougeole

NanoViricides NV-387 Épidémie De Rougeole Déclin Des Vaccins Étude Antivirale
BRIEF

published on 06/04/2025 at 13:00, 6 months 1 day ago

NanoViricides Prepares for Measles Drug Animal Study

NanoViricides NV-387 Measles Outbreak Vaccine Decline Antiviral Study
PRESS RELEASE

published on 06/04/2025 at 12:55, 6 months 1 day ago

NanoViricides Measles Drug Development Animal Study is Imminent
NanoViricides, Inc. announces progress in developing a Measles drug, NV-387, a broad-spectrum antiviral with potential to combat Measles outbreaks and vaccine failures

NV-387 NanoViricides Inc. Antiviral Clinical Stage Measles Drug
BRIEF

published on 05/28/2025 at 12:35, 6 months 8 days ago

NanoViricides sera présenté à la convention internationale BIO de Boston

NanoViricides Antiviral À Large Spectre Médicament NV-387 Convention BIO 2025 Technologies De Plate-forme
BRIEF

published on 05/28/2025 at 12:35, 6 months 8 days ago

NanoViricides to Showcase at Boston's BIO International Convention

NanoViricides Broad-spectrum Antiviral NV-387 Drug BIO Convention 2025 Platform Technologies
PRESS RELEASE

published on 05/28/2025 at 12:30, 6 months 8 days ago

NanoViricides to Present at the BIO International Convention in Boston on Monday, June 16, 2025
NanoViricides to present at BIO International Convention 2025 on June 16 in Boston, MA, showcasing breakthrough antiviral drug NV-387 with broad-spectrum efficacy and unique mechanism

NanoViricides NV-387 BIO International Convention Antiviral Drug Clinical Stage
BRIEF

published on 05/22/2025 at 12:35, 6 months 14 days ago

NanoViricides commente la nouvelle politique de la FDA concernant les vaccins contre la COVID-19

FDA NanoViricides Médicaments Antiviraux Politique De Vaccination Contre La COVID Stratégie De Santé Publique
BRIEF

published on 05/22/2025 at 12:35, 6 months 14 days ago

NanoViricides Comments on New FDA COVID Vaccine Policy

FDA NanoViricides Antiviral Drugs COVID Vaccine Policy Public Health Strategy

Accesswire

Published on 12/05/2025 at 21:45, 1 hour 5 minutes ago

When the Architecture Becomes Visible: The SMX Revaluation Explained
Published on 12/05/2025 at 21:30, 1 hour 20 minutes ago

The Identity Layer Beneath Everything: Why Markets Are Revaluing SMX All at Once
Published on 12/05/2025 at 21:20, 1 hour 30 minutes ago

Medicus Pharma Ltd. Enters Into $5.1 Million Warrant Inducement
Published on 12/05/2025 at 21:00, 1 hour 50 minutes ago

The Repricing Event: Why Multiple Global Industries Are Suddenly Moving Toward SMX
Published on 12/05/2025 at 20:25, 2 hours 25 minutes ago

The Feedback Loop: Why SMX's Adoption in One Industry Accelerates Interest in All the Others

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 22:15, 34 minutes ago

CPI PROPERTY GROUP - Changes in Shareholding and Board of Directors
Published on 12/05/2025 at 22:12, 38 minutes ago

EQS-Adhoc: CPI PROPERTY GROUP - Change to Distribution Policy
Published on 12/05/2025 at 18:58, 3 hours 52 minutes ago

EQS-Adhoc: HORNBACH Holding AG & Co. KGaA: Reduced earnings in Q3 2025/26 – Guidance for adjusted EBIT at previous year’s level still valid
Published on 12/05/2025 at 18:26, 4 hours 23 minutes ago

POS-Transaction in Own Shares
Published on 12/05/2025 at 18:15, 4 hours 34 minutes ago

Completion of merger to form Helvetia Baloise Holding Ltd

Les Echos

Published on 12/05/2025 at 17:18, 5 hours 32 minutes ago

La vidéo de la réunion de présentation des résultats 2024-2025 du 5 décembre 2025 est disponible
Published on 12/05/2025 at 17:18, 5 hours 32 minutes ago

The video of the 2024-2025 results presentation meeting on December 5, 2025, is available
Published on 12/05/2025 at 15:10, 7 hours 39 minutes ago

Mersen: Number of shares and voting rights as of November 30, 2025
Published on 12/05/2025 at 15:10, 7 hours 39 minutes ago

Mersen : nombre d'actions et de droits de vote au 30 novembre 2025
Published on 12/05/2025 at 13:58, 8 hours 51 minutes ago

RELATIF A LA MISE A DISPOSITION DU PUBLIC DE LA NOTE D'INFORMATION ET DES INFORMATIONS RELATIVES AUX CARACTERISTIQUES, NOTAMMENT JURIDIQUES, FINANCIERES ET COMPTABLES DE LEGRAND FRANCE

View all LES ECHOS COMFI WIRE